아이스큐어 메디컬ICCM 주가

Icecure Medical Ltd (ICCM) Q1 2026 Earnings Call Highlights: Robust Revenue Growth and ...

Icecure Medical Ltd (ICCM) reports a 26% revenue increase, driven by significant sales growth in North America and strategic FDA clearances.

12 Health Care Stocks Moving In Tuesday's After-Market Session

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that cryoablation and ProSense® were featured at the annual European Conference on Interventional Oncology ("ECIO") 2026, held in Basel, Switzerland on April 26 to 30, 2026.

IceCure Medical Features Cryoablation And ProSense At Annual ECIO 2026

At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free at a median

♻️ 재탕[6-K] 6-K — REPORT OF FOREIGN PRIVATE ISSUER

IceCure Medical : Initial Statement of Beneficial Ownership (Form 3)

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant...

[4] 내부자 거래

♻️ 재탕[4] 내부자 거래

[3] 3

Maxim Group Maintains Buy on Icecure Medical, Lowers Price Target to $1

Maxim Group analyst Anthony Vendetti maintains Icecure Medical (NASDAQ:ICCM) with a Buy and lowers the price target from $3 to $1.